Last Updated: May 6, 2026

Claims for Patent: 10,570,453

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,570,453

Title:	Method of predicting a predisposition to QT prolongation
Abstract:	The present invention describes an association between genetic polymorphisms in the ceramide kinase-like (CERKL) gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.
Inventor(s):	Christian Lavedan, Simona Volpi, Louis Licamele, Kendra Tomino Mack, Callie Michelle Heaton
Assignee:	Vanda Pharmaceuticals Inc
Application Number:	US15/956,052
Patent Claims:	1. A method comprising: characterizing, or having characterized, from a biological specimen obtained from a human individual an expression product of the individual's ceramide kinase-like (CERKL) gene; in the case that the characterized expression product is not associated with an increased risk of QT prolongation, administering to the individual a first quantity of iloperidone, an iloperidone metabolite, or a pharmaceutically-acceptable salt thereof; and in the case that the characterized expression product is associated with an increased risk of QT prolongation, administering to the individual a second quantity of iloperidone, an iloperidone metabolite, or a pharmaceutically-acceptable salt thereof, wherein the second quantity is less than the first quantity, wherein the genotype at the rs993648 single nucleotide polymorphism (SNP) locus for the characterized expression product is AG and is not associated with an increased risk of QT prolongation; and wherein the genotype at the rs993648 single nucleotide polymorphism (SNP) locus for the characterized expression product is non-AG and is associated with an increased risk of QT prolongation. 2. The method of claim 1, wherein the first quantity is 24 mg/day. 3. The method of claim 1, wherein the second quantity is less than 24 mg/day. 4. The method of claim 1, wherein the individual is suffering from long QT syndrome (LQTS). 5. The method of claim 1, further comprising: determining the individual's CYP2D6 genotype.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.